Literature DB >> 34687379

Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells.

Sibel Gunes1,2, Merve Nur Soykan3,4, Ayla Eker Sariboyaci3,4, Onur Uysal3,4, Tugba Semerci Sevimli3,4.   

Abstract

Human Klotho gene has many known functions such as anti-aging and anti-tumor, and decreased expression of this gene causes malignant formations in most types of cancer, including colon cancer. Interacting with TRAIL death receptors (DR4 and DR5) induces an apoptotic effect in cancer treatments by reducing the proliferation of cancer cells. The present study aimed to investigate downstream effect of overexpression of Klotho gene, which is known to have an antitumor effect on resistant human colon cancer cells, by examining its action on TRAIL death and decoy (DcR1 and DcR2) receptors for the first time. For this purpose, upregulation of human Klotho gene was achieved with CRISPR/Cas9-mediated system in resistant human colon cancer Caco-2 cells. To determine the effect of upregulation of Klotho gene on cancer cells evaluations with flow cytometry, WST-8, qRT-PCR, ELISA, and immunohistochemical analysis were performed. Then, Klotho gene was knocked out and its apoptotic effect was tested to find out whether it is due to overexpression of Klotho gene or not. Our results indicate that overexpression of Klotho gene in Caco-2 cells via CRISPR/Cas9-sensitized TRAIL death receptor DR4 suppresses the proliferation of cells by leading to apoptosis. Thus, this study conducted on apoptosis-resistant colon cancer cells may bring new insights about the role of Klotho gene in colon cancer.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR/Cas9; Caco-2 cells; Colon cancer; Klotho; TRAIL death receptor

Mesh:

Substances:

Year:  2021        PMID: 34687379     DOI: 10.1007/s12032-021-01595-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma.

Authors:  Yu Zhu; Le Xu; Jianping Zhang; Wenping Xu; Yujun Liu; Hankun Yin; Tao Lv; Huimin An; Li Liu; Hongyong He; Heng Zhang; Jing Liu; Jiejie Xu; Zongming Lin
Journal:  Cancer Sci       Date:  2013-03-29       Impact factor: 6.716

2.  Klotho expression is correlated to molecules associated with epithelial-mesenchymal transition in lung squamous cell carcinoma.

Authors:  Takayuki Ibi; Jitsuo Usuda; Tatsuya Inoue; Akira Sato; Kyoshiro Takegahara
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

3.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

4.  Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer.

Authors:  Jie Pan; Jing Zhong; Li Hong Gan; Shu Jie Chen; Hong Chuan Jin; Xian Wang; Liang Jing Wang
Journal:  Tumour Biol       Date:  2011-04-27

5.  Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.

Authors:  Xin-Xiang Li; Li-Yong Huang; Jun-Jie Peng; Lei Liang; De-Bing Shi; Hong-Tu Zheng; San-Jun Cai
Journal:  Int J Oncol       Date:  2014-05-09       Impact factor: 5.650

6.  Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.

Authors:  I Wolf; S Levanon-Cohen; S Bose; H Ligumsky; B Sredni; H Kanety; M Kuro-o; B Karlan; B Kaufman; H P Koeffler; T Rubinek
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

Review 7.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 8.  Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma.

Authors:  Xiaowei Tang; Yun Wang; Zhining Fan; Guozhong Ji; Min Wang; Jie Lin; Shu Huang; Stephen J Meltzer
Journal:  Lab Invest       Date:  2015-08-03       Impact factor: 5.662

9.  Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.

Authors:  Yan Wang; Lei Chen; Guochang Huang; Dongmei He; Juan He; Wei Xu; Chunying Zou; Feng Zong; Yan Li; Bo Chen; Shuanshuan Wu; Weihong Zhao; Jianqing Wu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 10.  Changes in expression of klotho affect physiological processes, diseases, and cancer.

Authors:  Nguyen Thi Xuan; Nong Van Hai
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

View more
  1 in total

Review 1.  Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

Authors:  Mohammed Fatih Rasul; Bashdar Mahmud Hussen; Abbas Salihi; Bnar Saleh Ismael; Paywast Jamal Jalal; Anna Zanichelli; Elena Jamali; Aria Baniahmad; Soudeh Ghafouri-Fard; Abbas Basiri; Mohammad Taheri
Journal:  Mol Cancer       Date:  2022-03-03       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.